Safety and efficacy of TNF a blockade in relapsing vasculitis

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Development of electronic form of the 1999 WHO/ISH hypertension guidelines.

  2002cited by this paper
• The DING protein: an autocrine growth-stimulatory protein related to the human synovial stimulatory protein.

  2002cited by this paper
• Anticoagulation with hirudin for continuous veno‐venous hemodialysis in liver transplantation

  2001cited by this paper
• Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study.

  2001cited by this paper
• Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

  2001cited by this paper
• Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety.

  2001cited by this paper
• Isolated digital vasculitis in a patient with rheumatoid arthritis: good response to tumour necrosis factor α blocking treatment

  2001cited by this paper
• Treatment of lupus with corticosteroids

  2001cited by this paper
• Meningeal involvement in Wegener granulomatosis.

  2000cited by this paper
• Use and interpretation of ambulatory blood pressure monitoring: recommendations of the British Hypertension Society

  2000cited by this paper
• Multispecific CD4+ T Cell Response to a Single 12-mer Epitope of the Immunodominant Heat-Shock Protein 60 of Yersinia enterocolitica in Yersinia-Triggered Reactive Arthritis: Overlap with the B27-Restricted CD8 Epitope, Functional Properties, and Epitope Presentation by Multiple DR Alleles1

  2000cited by this paper
• Synovial fluid lymphocyte proliferation in response to crude microbial antigens is not useful as a diagnostic test to specifically indicate a bacterial cause of arthritis.

  2000cited by this paper
• Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis.

  1999cited by this paper
• Inhibition of proinflammatory cytokine production by pravastatin.

  1999cited by this paper
• A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.

  1999cited by this paper
• Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease.

  1999cited by this paper
• Autoantibodies against C1q: view on clinical relevance and pathogenic roles

  1999cited by this paper
• Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group.

  1999cited by this paper
• Treatment with monoclonal anti-tumor necrosis factor alpha antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis.

  1999cited by this paper
• The 19 kDa protein of Yersinia enterocolitica O:3 is recognized on the cellular and humoral level by patients with Yersinia induced reactive arthritis.

  1999cited by this paper
• Balance of Th1/Th2 cytokines in thyroid autoantibody synthesis in vitro.

  1999cited by this paper
• Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

  1999cited by this paper
• Pachymeningitis in Wegener's granulomatosis.

  1998cited by this paper
• A hirudin-sensitive, growth-related proteinase from human fibroblasts.

  1998cited by this paper
• Communicating hydrocephalus secondary to diffuse meningeal spread of Wegener's granulomatosis: case report and literature review.

  1998cited by this paper
• CHARACTERIZATION OF THE SYNOVIAL T CELL RESPONSE TO VARIOUS RECOMBINANT YERSINH ANTIGENS IN YERSINIA ENTEROCOLITICA-TRIGGERED REACTIVE ARTHRITIS

  1998cited by this paper
• Clinical experience with leflunomide in rheumatoid arthritis

  1998cited by this paper
• Meningeal Involvement in Wegener's Granulomatosis Confirmed and Monitored by Positive Circulating Antineutrophil Cytoplasm in Cerebrospinal Fluid

  1997cited by this paper
• Adhesion molecules: a rheumatologic perspective.

  1997cited by this paper
• Wegener's granulomatosis with dural involvement as the initial clinical manifestation.

  1997cited by this paper
• Patterns of expression of tumor necrosis factor α, tumor necrosis factor β, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy

  1996cited by this paper
• Extremely active murine amyloid enhancing factor.

  1996cited by this paper
• A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes.

  1996cited by this paper
• Recent advances in the pathogenesis of reactive arthritis.

  1996cited by this paper
• Biochemical characterization and microsequencing of a 205-kDa synovial protein stimulatory for T cells and reactive with rheumatoid factor containing sera.

  1996cited by this paper
• The molecular basis of reactive amyloidosis.

  1995cited by this paper
• Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus.

  1995cited by this paper
• Neuro-ophthalmic manifestations of meningocerebral inflammation from the limited form of Wegener's granulomatosis.

  1995cited by this paper
• Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.

  1994cited by this paper
• Pravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptor activity in macrophages: in vitro and in vivo studies.

  1994cited by this paper
• Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet's disease. A comparative study with familial Mediterranean fever and healthy subjects.

  1993cited by this paper
• Lupus psychosis: differentiation from the steroid-induced state.

  1993cited by this paper
• Intracranial Wegener's granulomatosis

  1993cited by this paper
• Reduced synovial membrane macrophage numbers, ELAM-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis.

  1993cited by this paper
• Neurological involvement in Wegener's granulomatosis: An analysis of 324 consecutive patients at the Mayo Clinic

  1993cited by this paper
• Expression of vascular cell adhesion molecule-1 in fibroblastlike synoviocytes after stimulation with tumor necrosis factor.

  1992cited by this paper
• Isolation and culture of synovial microvascular endothelial cells. Characterization and assessment of adhesion molecule expression.

  1992cited by this paper
• Comparison of autoantibodies to the collagen-like region of C1q in hypocomplementemic urticarial vasculitis syndrome and systemic lupus erythematosus.

  1992cited by this paper
• Crush and smear technique for rapid detection and semiquantitation of amyloid deposition.

  1991cited by this paper
• Cationic Yersinia antigen-induced chronic allergic arthritis in rats. A model for reactive arthritis in humans.

  1991cited by this paper
• Collagen autoantibodies in patients with vasculitis and systemic lupus erythematosus.

  1991cited by this paper
• Production of TNF-alpha and IL-1 in active Behçet's disease.

  1990cited by this paper
• Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin.

  1990cited by this paper
• Phenotypic profile of major synovial cell populations in longstanding psoriatic arthritis.

  1987cited by this paper
• The classical complement pathway: activation and regulation of the first complement component.

  1985cited by this paper
• Characterization of C1q-binding IgG complexes in systemic lupus erythematosus.

  1984cited by this paper
• The 1982 revised criteria for the classification of systemic lupus erythematosus.

  1982cited by this paper
• Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

  1981cited by this paper
• Purification and radiolabeling of human C1q.

  1981cited by this paper
• Stimulation of rheumatoid synovial cell collagenase and prostaglandin production by partially purified lymphocyte-activating factor (interleukin 1).

  1981cited by this paper
• Subacute meningitis heralding a diffuse granulomatous angiitis

  1977cited by this paper
• Hospital outbreak of Yersinia enterocolitica infection.

  1973cited by this paper
• Acute adverse reactions to prednisone in relation to dosage

  1972cited by this paper
• Prednisone side-effects and serum-protein levels. A collaborative study.

  1971cited by this paper
• The rate of visual loss in Behçet's disease.

  1970cited by this paper

• Granulomatosis with Polyangiitis

  2021cites this paper
• Infliximab v léčbě Wegenerovy granulomatózy: kazuistika

  2019cites this paper
• Granulomatosis with Polyangiitis (Wegener's Granulomatosis): Evolving Concepts in Treatment

  2018cites this paper
• Antineutrophil cytoplasmic antibodies associated vasculitis in patient with Crohn's disease treated with adalimumab.

  2017cites this paper
• Vasculitis asociada a anticuerpo anticitoplasma de neutrófilo en paciente con enfermedad de Crohn en tratamiento con adalimumab

  2017cites this paper
• CanVasc Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitides

  2016cites this paper
• Biologics for the treatment of autoimmune renal diseases

  2016cites this paper
• Biologic agents in the treatment of glomerulonephritides

  2015cites this paper
• Biological drugs in ANCA-associated vasculitis.

  2015cites this paper
• Anti-TNF-Alpha Therapy and Systemic Vasculitis

  2014cites this paper
• Biologics for ANCA-associated vasculitis.

  2014cites this paper
• Vascularites associées aux anticorps anticytoplasme des polynucléaires neutrophiles : nouveaux traitements

  2014cites this paper
• The role of biologics in treatment of ANCA-associated vasculitis

  2012cites this paper
• Historia del tratamiento de las vasculitis primarias

  2012cites this paper
• Historia del tratamiento de las vasculitis primarias History of treatment of primary vasculitis

  2012cites this paper
• TNF-α Blocker Therapy and Solid Malignancy Risk in ANCA-Associated Vasculitis

  2012cites this paper
• Novel Therapies for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

  2012cites this paper
• Biologic agents in systemic vasculitis.

  2011cites this paper
• New indications for biological therapies

  2011cites this paper
• Wegener's granulomatosis.

  2011cites this paper
• Recommendations for the use of biologic therapy from the Italian Society for Rheumatology: off-label use.

  2011cites this paper
• Evidencias sobre la eficacia de los tratamientos biológicos en las vasculitis sistémicas

  2011cites this paper
• Biologic Agents for the Treatment of Systemic Vasculitis

  2011cites this paper
• Clinical manifestations and treatment of Wegener's granulomatosis.

  2010cites this paper
• Prospective study of TNFalpha blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement.

  2010cites this paper
• Anti-TNF-α treatment in Behçet's disease with cerebral vasculitis: A case report

  2010cites this paper
• Anti-cytokine targeted therapies for ANCA-associated vasculitis.

  2010cites this paper
• Development of myeloperoxidase-antineutrophil cytoplasmic antibody-associated renal vasculitis in a patient receiving treatment with anti-tumor necrosis factor-a

  2010cites this paper
• Development of myeloperoxidase-antineutrophil cytoplasmic antibody-associated renal vasculitis in a patient receiving treatment with anti-tumor necrosis factor-α

  2010cites this paper
• Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

  2009cites this paper
• ANCA-associated vasculitides: pathogenetic aspects and current evidence-based therapy.

  2009cites this paper
• Novel strategy for the treatment of refractory vasculitis syndrome.

  2009cites this paper
• Respiratory Disease Antibody-Associated Vasculitides and Antineutrophil Cytoplasmic

  2009cites this paper
• Wegener-Granulomatose und mikroskopische Polyangiitis

  2009cites this paper
• [Anti-TNFalpha therapy in systemic autoimmune and/or inflammatory diseases].

  2009cites this paper
• Advances in the use of biologic agents for the treatment of systemic vasculitis

  2009cites this paper
• Antineutrophil cytoplasmic antibody-associated vasculitides and respiratory disease.

  2009cites this paper
• Newer therapies for vasculitis.

  2009cites this paper
• Treatment of refractory and/or severe ANCA-associated systemic necrotizing vasculitides.

  2008cites this paper
• Immunotherapy for antineutrophil cytoplasmic antibody-associated vasculitis: challenging the therapeutic status quo?

  2008cites this paper
• Drug Insight: anti-tumor necrosis factor therapies for the vasculitic diseases

  2008cites this paper
• Wegener’s granulomatosis: an update on diagnosis and therapy

  2008cites this paper
• Respiratory System Involvement in Antineutrophil Cytoplasmic-Associated Systemic Vasculitides

  2007cites this paper
• Antineutrophil cytoplasmic antibody-associated vasculitides.

  2007cites this paper
• [Off-label use of biologic agents in the treatment of dermatosis, Part 1: infliximab and adalimumab].

  2007cites this paper
• Cytokines in glomerulonephritis.

  2007cites this paper
• Tumor necrosis factor as a therapeutic target of rheumatologic disease

  2007cites this paper
• Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2).

  2007cites this paper
• Update on the use of biologics in primary systemic vasculitides

  2007cites this paper
• Chapter 8 ANCA-Associated Vasculitis: Clinical Features and Treatment

  2007cites this paper
• Vascularites associées aux anticorps anticytoplasme des polynucléaires

  2007cites this paper
• Uso de fármacos biológicos en dermatosis fuera de la indicación aprobada. Primera parte: infliximab y adalimumab

  2007cites this paper
• TNF blockade in orphan rheumatic diseases

  2007cites this paper
• Infliximab as rescue therapy in three cases of paediatric Wegener's granulomatosis.

  2006cites this paper
• Advances in the treatment of small vessel vasculitis.

  2006cites this paper
• Treatment of inflammatory dermatoses by tumour necrosis factor antagonists

  2006cites this paper
• Wegener’s granulomatosis: Is biologic therapy useful?

  2006cites this paper
• Infliximab in dermatology, gastroenterology, and off-label use

  2006cites this paper
• Is there a role for TNF-alpha in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases.

  2006cites this paper
• Off-label uses of biologic agents in dermatology: a 2006 update.

  2006cites this paper
• Autoimmune diseases in children

  2005cites this paper
• An update on the classification and treatment of vasculitic neuropathy.

  2005cites this paper
• Current state of tumour necrosis factor α blockade in Wegener’s granulomatosis

  2005cites this paper
• Successful treatment of childhood onset refractory polyarteritis nodosa with tumor necrosis factor alpha blockade.

  2005cites this paper
• How to induce remission in primary systemic vasculitis.

  2005cites this paper
• Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis.

  2004cites this paper
• Prolonged Treatment with Low-Dose Intravenous Pulse Cyclophosphamide May Reduce Rate of Relapse in ANCA-Associated Vasculitis

  2004cites this paper
• Tumor necrosis factor α blockade with infliximab for refractory uveitis and scleritis

  2004cites this paper
• Multiple facets of macrophages in renal injury.

  2004cites this paper
• Wegener's granulomatosis in pregnancy: a novel approach to management.

  2004cites this paper
• Renal function in rheumatoid arthritis patients treated with methotrexate and infliximab.

  2004cites this paper
• The utility of tumour necrosis factor blockade in orphan diseases

  2004cites this paper
• Wegener's granulomatosis: current and upcoming therapies

  2003cites this paper
• Upcoming biologic agents for the treatment of rheumatic diseases

  2003cites this paper
• ANCA and Neutrophil Biology

  2003cites this paper
• Current Attitudes to the Therapy of Vasculitis

  2003cites this paper
• Therapeutischer Einsatz der Tumor‐Nekrose‐Faktor‐α‐Hemmer Infliximab und Etanercept bei entzündlichen Hauterkrankungen

  2003cites this paper
• Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study.

  2003cites this paper
• [Therapeutic application of TNF-alpha inhibitors infliximab and etanercept in inflammatory skin disorders].

  2003cites this paper
• Immunotherapy for autoimmune and inflammatory renal diseases

  1998cites this paper